摘要
目的对比分析替吉奥(TGOPC,S-1)与卡培他滨(Xeloda)分别联合奥沙利铂(Oxaliplatin,L-OHP)治疗晚期结直肠癌(colorectal cancer,CRC)的临床疗效。方法随机选取接受治疗晚期结肠癌患者150例,采用S-1联合L-OHP治疗方案75例,即为A组;75例采用Xeloda联合L-OHP治疗方案,即为B组。两组每治疗3个周期后对疗效和毒性进行评价对比分析。结果 A、B两组患者一般资料对比,差异均无统计学意义(P>0.05)。A、B两组ORR和DCR对比分析,差异均无统计学意义(P=0.825,P=0.698)。A组患者4例失去联系,B组患者2例失去联系,中位随访时间为12个月。A组和B组中位疾病进展时间分别为8.8个月和8.2个月,A、B两组对比,差异无统计学意义(χ~2=2.741,P=0.124)。A、B两组大多不良反应出现在Ⅰ和Ⅱ阶段,Ⅲ和Ⅳ阶段出现较少,但都没有出现严重不良反应而停止服药的,且没有在治疗期间出现死亡病例。A组有2例患者表现为Ⅳ度血小板减少,通过减少服用S-1药量后完成化疗;B组有4例患者表现Ⅲ度手足综合症,也是通过减少Xeloda药量后完成化疗,两组其他患者都可以耐受。骨髓抑制、胃肠道反应、肝功能异常、手足综合征和口腔黏膜炎为A和B两组主要共有的不良反应,在两组对比中,A组的血小板减少发生率比B组的高,差异有统计学意义(P=0.042);A组的手足综合症发生率比B组的低,差异有统计学意义(P=0.031)。结论 A组和B组的治疗方案疗效相近;S-1联合L-OHP治疗晚期CRC患者确切有效,值得推广。
Objective Comparative analysis of clinical efficacy of Tegrio(TGOPC,S-1)and Capecitabine(Xeloda)combined with Oxaliplatin(L-OHP)in the treatment of advanced colorectal cancer(CRC). Methods One hundred and fifty patients with advanced colon cancer were randomly selected.Seventy-five patients were treated with S-1 combined with L-OHP,ie,group A;75 patients were treated with Xeloda combined with L-OHP,ie group B.The efficacy and toxicity of each group after 3 cycles of treatment were evaluated and compared. Results There was no significant difference in the general data between A and B groups( P >0.05).There was no significant difference in ORR and DCR between group A and B( P =0.825, P =0.698).In group A,4 patients lost contact,2 patients in group B lost contact,and the median follow-up time was 12 months.The median time to disease progression of group A and group B was 8.8 months and 8.2 months respectively.There was no significant difference between groups A and B(χ 2=2.741, P =0.124).Most of the adverse reactions against groups A and B appeared in stages Ⅰ and Ⅱ.There were fewer stages Ⅲ and Ⅳ,but no severe adverse reactions occurred and they stopped taking the drug.There were no deaths during the treatment period.In group A,2 patients presented with grade Ⅳ thrombocytopenia and completed chemotherapy by reducing the dose of S-1;in group B,4 patients showed grade Ⅲ hand-foot syndrome,and chemotherapy was also completed by reducing the Xeloda dose.Other patients can tolerate.Myelosuppression,gastrointestinal reactions,abnormal liver function,hand-foot syndrome,and oral mucositis were the main common adverse reactions in the A and B groups.In the two groups,the incidence of thrombocytopenia was higher in group A than in group B.The difference was statistically significant( P =0.042).The incidence of hand-foot syndrome in group A was lower than that in group B.The difference was statistically significant( P =0.031). Conclusion Regimen groups A and B of similar efficacy;S-1 L-OHP combined treatment of p
作者
何丽琳
沈永祥
HE Lilin;SHEN Yongxiang(Tianmen First People's Hospital of Hubei province,Tianmen,431700)
出处
《实用癌症杂志》
2019年第1期128-131,共4页
The Practical Journal of Cancer
